Welcome to our dedicated page for Intelligent Bio Solutions news (Ticker: INBS), a resource for investors and traders seeking the latest updates and insights on Intelligent Bio Solutions stock.
Intelligent Bio Solutions Inc. develops medical technology for rapid, non-invasive testing, centered on fingerprint sweat drug screening. Its updates commonly cover the Intelligent Fingerprinting Drug Screening System, Drug Screening Cartridges, DSR-Plus reader, lateral-flow test strip manufacturing, and the reader-and-consumable sales model used in workplace testing markets outside the United States.
Company news also focuses on clinical and regulatory work supporting an FDA 510(k) pathway for codeine detection, cybersecurity and validation testing tied to the system, European patent protection for fingerprint chemical analysis, manufacturing scale-up for readers and cartridges, customer deployments in the United Kingdom, and periodic revenue reports by product category.
Intelligent Bio Solutions (Nasdaq: INBS) reported fiscal Q3 2026 revenue of $1.06 million, up 46% year-over-year, with cartridge sales rising 59% and contributing 66% of revenue. Gross margin reached 50.5%, nine-month revenue grew 39% to $3.07 million, and cash was $6.86 million.
The company highlighted progress toward FDA 510(k) clearance, a new manufacturing partnership, a Bouygues UK rollout, and its eighth European patent for its fingerprint drug screening technology.
Intelligent Bio Solutions (Nasdaq: INBS) launched a validation study on April 20, 2026 to accelerate its Intelligent Fingerprinting Drug Screening System from a current ~10-minute result to a target sub-3-minute (two-minute goal) analysis time.
The study is preliminary; INBS is deployed in U.S. Forensic Use Only settings and is pursuing FDA 510(k) clearance for opiate codeine. The company cites a U.S. roadside testing market of $1.17B (2023) projected to $1.62B by 2030 and a global drug screening TAM of $16.7B through 2030.
Intelligent Bio Solutions (Nasdaq: INBS) completed independent penetration testing on April 17, 2026, identifying no major vulnerabilities and implementing additional security upgrades ahead of its FDA 510(k) submission.
Upgrades include enhanced encrypted identification tags and firmware safeguards to protect donor data and ensure authorized updates. According to the company, these steps strengthen the 510(k) submission and align the technology with evolving FDA medical device cybersecurity guidance, which the company says could enable U.S. market expansion if FDA clearance is obtained.
Intelligent Bio Solutions (Nasdaq: INBS) completed its initial clinical Cut-off Study for the Intelligent Fingerprinting Drug Screening System detecting codeine in 40 adults, with data analysis finished by end of March 2026.
The company began a multi-site Method Comparison & Usability Study (expected complete end of June 2026) and will run an Interference Study (expected complete end of July 2026) to support an FDA 510(k) submission comparing results to an FDA-cleared predicate and LC-MS/MS confirmation.
Intelligent Bio Solutions (Nasdaq: INBS) announced on March 26, 2026 that it received European Patent EP3752831, its eighth European patent.
The patent protects an advance that correlates fingerprint chemical findings with fingerprint deposition volume, strengthening the company’s European IP around fingerprint sweat drug screening, lateral flow analysis, sample cartridges, and test strip readers.
Intelligent Bio Solutions (NASDAQ: INBS) confirmed first shipment and deployment of readers manufactured with Syrma Johari, validating scaled production and ISO 13485/MDSAP compliance. The partnership increases reader capacity ~4x and is on track to deliver >40% annual production cost savings, targeting ~20 percentage-point gross margin improvement. INBS also doubled in-house lateral flow strip capacity, improving vertical integration, R&D speed, and enabling expanded drug-panel cartridges ahead of planned U.S. market entry in 2026.
Intelligent Bio Solutions (Nasdaq: INBS) announced a partnership with Bouygues UK, a subsidiary of Bouygues Construction, to deploy INBS’s fingerprint drug screening across 13 UK project sites. Bouygues Construction reported a turnover of €10.3 billion in 2024 and employs 35,600 globally. According to the company, a joint ROI analysis showed substantial cost savings versus third-party testing, and the UK rollout is positioned as a foundation for potential wider expansion across Bouygues operations.
Intelligent Bio Solutions (Nasdaq: INBS) reported fiscal Q2 revenue of $896,774, up 48% YoY, and six‑month revenue of $2.01M, up 36% YoY. Reader sales surged 104% YoY to $246,519 in Q2; cartridges rose 33% YoY to $516,754.
Gross profit margin for H1 fiscal 2026 improved to 49% (from 39%). The company closed a $10.0M private placement (net proceeds $9.40M received Jan 2, 2026) and announced manufacturing and commercial partnerships while advancing FDA 510(k) studies.
Intelligent Bio Solutions (Nasdaq: INBS) expects preliminary unaudited fiscal Q2 2026 revenue to rise about 48% YoY, and fiscal H1 2026 total revenue to be approximately $2.01 million (up 36% YoY).
Reader sales are expected to increase ~104% YoY in Q2 while cartridge sales are up ~33% Q2 / 38% H1, with accessories/training also growing. Results are preliminary and subject to quarter-end close and Form 10-Q filing during the week of Feb 9, 2026.
Intelligent Bio Solutions (Nasdaq: INBS) initiated clinical studies on Jan 28, 2026 to support an FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System targeting codeine detection.
The first cohort (40 adults) will use the DSR-Plus reader and fingerprint cartridges, include LC-MS/MS confirmation and predicate-device comparisons; full data analysis is expected by end of March 2026 for incorporation into the 510(k) package.